ESR1 and breast cancer: The [18F]-FES-PET is a clear example of a non-invasive imaging modality that provides the ER status of the primary tumor and all metastases and, secondly, allows the evaluation of treatment response, monitoring the therapeutic efficacy (e.g., fulvestrant therapy in breast cancer patients) and therapy decision making in relation to the [18F]-FES-PET scan outcome.